NovoCure Ltd. (NVCR) Insider Trading

Last 12 months

Insiders sold $3.25M and bought nothing on the open market.

None of the selling was scheduled in advance under a 10b5-1 plan. Executive Chairman William F Doyle sold $933k on Mar 3, 18% of their stake, outside a plan. The last open-market buy by an executive or director was in Sep 2025.

Net open-market

−$3.25M

0 buys · 20 sales

Under a 10b5-1 plan

of the value sold

Insiders who bought / sold

0 / 14

executives and directors

Last open-market buy

Sep 2025

Sep 5, 2025

Get an email when NVCR's executives or directors buy, or make a large sale outside a plan.

Trades · last 2 years

Date	Insider	Trade	Shares	Price	Value	Of their stake	Filing
Jun 4	Frank X Leonard Chief Executive Officer	SoldNo plan	34,273	$17.93	$615k	6.9%	Form 4
Jun 2	Kristin Stafford Director	SoldNo plan	2,945	$15.77	$46k	21%	Form 4
Jun 2	Allyson J Ocean Director	SoldNo plan	2,945	$15.77	$46k	21%	Form 4
Jun 2	Timothy J Scannell Director	SoldNo plan	2,945	$15.77	$46k	17%	Form 4
Jun 2	W Anthony Vernon Director	SoldNo plan	2,945	$15.77	$46k	1.5%	Form 4
Jun 2	David Hung Director	SoldNo plan	2,945	$15.77	$46k	13%	Form 4
Jun 2	Gabriel Leung Director	SoldNo plan	2,945	$15.77	$46k	3.2%	Form 4
Jun 2	Jeryl L Hilleman Director	SoldNo plan	2,945	$15.77	$46k	18%	Form 4
Mar 4 – 5	Mukund Paravasthu Chief Operating Officer	SoldNo plan 2 parts	48,623	$13.72 average	$667k	40%	Form 4
Mar 4	Christoph Brackmann Chief Financial Officer	SoldNo plan	6,412	$13.31	$85k	3.4%	Form 4
Mar 4	Nicolas Leupin Former Chief Medical Officer	SoldNo plan	1,100	$13.31	$15k	1.1%	Form 4
Mar 4	Michal Nath Puri Chief Human Resources Officer	SoldNo plan	1,100	$13.31	$15k	0.5%	Form 4
Mar 4	Frank X Leonard Chief Executive Officer	SoldNo plan	5,607	$13.31	$75k	1.1%	Form 4
Mar 4	Uri Weinberg Chf Medical and Innovation Ofr	SoldNo plan	6,412	$13.31	$85k	2.3%	Form 4
Mar 3	William F Doyle Executive Chairman	SoldNo plan 2 parts	71,887	$12.98 average	$933k	18%	Form 4
Feb 27 – Mar 2	Mukund Paravasthu Chief Operating Officer	SoldNo plan 2 parts	1,963	$13.62 average	$27k	2.5%	Form 4
Feb 27 – Mar 2	Frank X Leonard Chief Executive Officer	SoldNo plan 2 parts	16,966	$13.59 average	$231k	4.6%	Form 4
Feb 27 – Mar 2	Uri Weinberg Chf Medical and Innovation Ofr	SoldNo plan 2 parts	10,733	$13.68 average	$147k	4.6%	Form 4
Feb 27	Nicolas Leupin Former Chief Medical Officer	SoldNo plan	1,029	$13.66	$14k	1.0%	Form 4
Feb 27	Michal Nath Puri Chief Human Resources Officer	SoldNo plan	1,441	$13.66	$20k	0.9%	Form 4
Sep 5, 2025	Ashley Cordova Chief Executive Officer	Bought	81,550	$12.22	$997k	23%	Form 4
Jul 29, 2025	Christoph Brackmann Chief Financial Officer	Bought 3 parts	20,000	$11.59 average	$232k	17%	Form 4
Jun 3, 2025	Kristin Stafford Director	SoldNo plan	999	$17.28	$17k	25%	Form 4
Jun 3, 2025	Gabriel Leung Director	SoldNo plan	999	$17.31	$17k	1.2%	Form 4
Jun 3, 2025	Martin J. Madden Director	SoldNo plan	999	$17.19	$17k	5.1%	Form 4
Jun 3, 2025	Timothy J Scannell Director	SoldNo plan	999	$17.32	$17k	14%	Form 4
Jun 3, 2025	Jeryl L Hilleman Director	SoldNo plan	999	$17.26	$17k	15%	Form 4
Jun 3, 2025	Allyson J Ocean Director	SoldNo plan	999	$17.29	$17k	25%	Form 4
Jun 3, 2025	W Anthony Vernon Director	SoldNo plan	999	$17.35	$17k	0.6%	Form 4
Jun 3, 2025	David Hung Director	SoldNo plan	999	$17.30	$17k	7.6%	Form 4
Jun 2, 2025	Frank X Leonard EVP, Pres., Novocure Oncology	Sold10b5-1 plan 3 parts	30,196	$17.50 average	$528k	15%	Form 4
May 3, 2025	Mukund Paravasthu Chief Operating Officer	SoldNo plan	592	$17.91	$11k	0.7%	Form 4
Mar 3, 2025	Uri Weinberg Chief Innovation Officer	SoldNo plan	268	$18.92	$5k	0.2%	Form 4
Mar 3, 2025	Frank X Leonard EVP, Pres., Novocure Oncology	SoldNo plan	2,527	$18.54	$47k	1.7%	Form 4
Mar 3, 2025	Ashley Cordova Chief Executive Officer	SoldNo plan	2,053	$18.54	$38k	1.0%	Form 4
Mar 3, 2025	Mukund Paravasthu Chief Operating Officer	SoldNo plan	250	$18.54	$5k	0.8%	Form 4
Feb 28, 2025	Uri Weinberg Chief Innovation Officer	SoldNo plan 2 parts	4,637	$18.75 average	$87k	2.7%	Form 4
Feb 27, 2025 – Feb 28, 2025	Frank X Leonard EVP, Pres., Novocure Oncology	SoldNo plan 3 parts	15,036	$19.70 average	$296k	9.3%	Form 4
Feb 27, 2025 – Feb 28, 2025	Ashley Cordova Chief Executive Officer	SoldNo plan 3 parts	13,494	$19.72 average	$266k	6.1%	Form 4
Feb 27, 2025 – Feb 28, 2025	Mukund Paravasthu Chief Operating Officer	SoldNo plan 3 parts	2,014	$19.70 average	$40k	6.4%	Form 4

Jun 4No plan
Frank X Leonard
Chief Executive Officer · sold 34,273 at $17.93
$615k
6.9% of stake
Jun 2No plan
Kristin Stafford
Director · sold 2,945 at $15.77
$46k
21% of stake
Jun 2No plan
Allyson J Ocean
Director · sold 2,945 at $15.77
$46k
21% of stake
Jun 2No plan
Timothy J Scannell
Director · sold 2,945 at $15.77
$46k
17% of stake
Jun 2No plan
W Anthony Vernon
Director · sold 2,945 at $15.77
$46k
1.5% of stake
Jun 2No plan
David Hung
Director · sold 2,945 at $15.77
$46k
13% of stake
Jun 2No plan
Gabriel Leung
Director · sold 2,945 at $15.77
$46k
3.2% of stake
Jun 2No plan
Jeryl L Hilleman
Director · sold 2,945 at $15.77
$46k
18% of stake
Mar 4 – 5No plan
Mukund Paravasthu
Chief Operating Officer · sold 48,623 at avg $13.72
$667k
40% of stake
Mar 4No plan
Christoph Brackmann
Chief Financial Officer · sold 6,412 at $13.31
$85k
3.4% of stake
Mar 4No plan
Nicolas Leupin
Former Chief Medical Officer · sold 1,100 at $13.31
$15k
1.1% of stake
Mar 4No plan
Michal Nath Puri
Chief Human Resources Officer · sold 1,100 at $13.31
$15k
0.5% of stake
Mar 4No plan
Frank X Leonard
Chief Executive Officer · sold 5,607 at $13.31
$75k
1.1% of stake
Mar 4No plan
Uri Weinberg
Chf Medical and Innovation Ofr · sold 6,412 at $13.31
$85k
2.3% of stake
Mar 3No plan
William F Doyle
Executive Chairman · sold 71,887 at avg $12.98
$933k
18% of stake
Feb 27 – Mar 2No plan
Mukund Paravasthu
Chief Operating Officer · sold 1,963 at avg $13.62
$27k
2.5% of stake
Feb 27 – Mar 2No plan
Frank X Leonard
Chief Executive Officer · sold 16,966 at avg $13.59
$231k
4.6% of stake
Feb 27 – Mar 2No plan
Uri Weinberg
Chf Medical and Innovation Ofr · sold 10,733 at avg $13.68
$147k
4.6% of stake
Feb 27No plan
Nicolas Leupin
Former Chief Medical Officer · sold 1,029 at $13.66
$14k
1.0% of stake
Feb 27No plan
Michal Nath Puri
Chief Human Resources Officer · sold 1,441 at $13.66
$20k
0.9% of stake
Sep 5, 2025
Ashley Cordova
Chief Executive Officer · bought 81,550 at $12.22
$997k
23% of stake
Jul 29, 2025
Christoph Brackmann
Chief Financial Officer · bought 20,000 at avg $11.59
$232k
17% of stake
Jun 3, 2025No plan
Kristin Stafford
Director · sold 999 at $17.28
$17k
25% of stake
Jun 3, 2025No plan
Gabriel Leung
Director · sold 999 at $17.31
$17k
1.2% of stake
Jun 3, 2025No plan
Martin J. Madden
Director · sold 999 at $17.19
$17k
5.1% of stake
Jun 3, 2025No plan
Timothy J Scannell
Director · sold 999 at $17.32
$17k
14% of stake
Jun 3, 2025No plan
Jeryl L Hilleman
Director · sold 999 at $17.26
$17k
15% of stake
Jun 3, 2025No plan
Allyson J Ocean
Director · sold 999 at $17.29
$17k
25% of stake
Jun 3, 2025No plan
W Anthony Vernon
Director · sold 999 at $17.35
$17k
0.6% of stake
Jun 3, 2025No plan
David Hung
Director · sold 999 at $17.30
$17k
7.6% of stake
Jun 2, 202510b5-1 plan
Frank X Leonard
EVP, Pres., Novocure Oncology · sold 30,196 at avg $17.50
$528k
15% of stake
May 3, 2025No plan
Mukund Paravasthu
Chief Operating Officer · sold 592 at $17.91
$11k
0.7% of stake
Mar 3, 2025No plan
Uri Weinberg
Chief Innovation Officer · sold 268 at $18.92
$5k
0.2% of stake
Mar 3, 2025No plan
Frank X Leonard
EVP, Pres., Novocure Oncology · sold 2,527 at $18.54
$47k
1.7% of stake
Mar 3, 2025No plan
Ashley Cordova
Chief Executive Officer · sold 2,053 at $18.54
$38k
1.0% of stake
Mar 3, 2025No plan
Mukund Paravasthu
Chief Operating Officer · sold 250 at $18.54
$5k
0.8% of stake
Feb 28, 2025No plan
Uri Weinberg
Chief Innovation Officer · sold 4,637 at avg $18.75
$87k
2.7% of stake
Feb 27, 2025 – Feb 28, 2025No plan
Frank X Leonard
EVP, Pres., Novocure Oncology · sold 15,036 at avg $19.70
$296k
9.3% of stake
Feb 27, 2025 – Feb 28, 2025No plan
Ashley Cordova
Chief Executive Officer · sold 13,494 at avg $19.72
$266k
6.1% of stake
Feb 27, 2025 – Feb 28, 2025No plan
Mukund Paravasthu
Chief Operating Officer · sold 2,014 at avg $19.70
$40k
6.4% of stake

How to read this. Insiders sell for many reasons: taxes, diversifying, a house. Open-market buys are rarer and say more. A 10b5-1 plan is a trading schedule set up months in advance, so those sales were not timed on news. Large holders (funds and 10% owners) are listed under Everything but not counted as insiders. If you own or watch NVCR, we send a push when an executive buys or makes a large sale outside a plan.

Source: SEC Form 4 filings, filed within two business days of each trade and checked for new ones every hour.

Related stocks: Surgical & Medical Instruments & Apparatus

UFPTUFP Technologies Inc.

GKOSGlaukos Corporation

ATECAlphatec Holdings Inc.

BVSBioventus Inc.

IRTCIrhythm Technologies Inc.

ATRCAtriCure, Inc.

OFIXOrthofix Medical Inc.

INSPInspire Medical Systems, Inc.

Spot a number that looks wrong? Check it in NVCR's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

2 of 2 free stocks used today

Keep analysing NVCR

Create a free account and get 14 days of Premium: every stock and every tool.

Unlimited stocksQuality, fair value and dividends for 10,000+ stocks
Stock screenerFilter on quality, valuation and dividend safety
Portfolio trackerReal return, dividend calendar and portfolio quality
Editable DCFChange the assumptions and watch fair value move
Compare side by sideUp to 10 stocks in one table
Unlimited alertsPrice, P/E, Quality Score and yield

No card. Moves to Free after, unless you upgrade.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.